Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.88 |
| ▸ | MEN1 | O00255 | 6/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.62 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.62 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.62 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885865 | 0.93 | KMT2A (0.75) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6524477 | 0.89 | RAB9A (1.00) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6955649 | 0.87 | MAPT (1.00) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14859923 | 0.82 | ALDH1A1 (0.81) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19376048 | 0.80 | PTPN7 (0.69) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31657816 | 0.80 | PTPN7 (0.69) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL158616 | 0.80 | RAB9A (0.81) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14433475 | 0.80 | LMNA (0.64) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9530086 | 0.79 | MAPT (0.76) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14434554 | 0.79 | MEN1 (0.65) | KMT2AMEN1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096473-A1 | Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction | PARKER HUGHES INSTITUTE (US) | 2005-05-05 | — | — | US | disclosed |
| US-6794541-B2 | REACTING 1,1'-THIOCARBONYLDIIMIDAZOLE WITH AN AMINE SUCH AS BENZYLAMINE TO FORM VARIOUS THIOUREA PRODUCTS; KILLING CANCER CELLS; TREATING LEUKEMIA | PARKER HUGHES INSTITUTE | 2004-09-21 | — | — | US | disclosed |
| US-20020103380-A1 | Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction | PARKER HUGHES INSTITUTE | 2002-08-01 | — | — | US | disclosed |
| WO-2000056681-A9 | THIOUREA AND UREA LIQUID-PHASE COMBINATORIAL LIBRARIES: SYNTHESIS AND APOPTOSIS INDUCTION | PARKER HUGHES INST (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096473-A1 | Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction | CASP3, MCL1, BAD | KMT2A 3633/4885MEN1 4186/4885SMN1; SMN2 3766/4885 |
| US-20020103380-A1 | Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction | CASP3, MCL1, BAD | KMT2A 3633/4885MEN1 4186/4885SMN1; SMN2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.